$69 postpage LB

Is Australia winning COVID-19 Battle? Vaccine in March, no patients on ventilator support

  • November 24, 2020 05:31 PM AEDT
  • Hina Chowdhary
    Director, Equities Research Hina Chowdhary
    1394 Posts

    Hina Chowdhary is the Director, Equity Research at Kalkine and has an extensive experience of about 15 years in the area of Research, which includes 5+ years in Equities Research particularly.She has earned a Master of Science degree from the renowne...

Is Australia winning COVID-19 Battle? Vaccine in March, no patients on ventilator support

Summary

  • The Australian government announced a significant breakthrough to start the rollout of a potential COVID-19 vaccine by March next year.
  • The government said immunisations for healthcare workers would commence in March 2021 followed by the aged people.
  • Australia has already locked four COVID-19 vaccine deals with major vaccine developers.
  • In another positive news for the country, there were no patients dependent on ventilator support as of 24 November.
Gold MTF non-AMP

Good news around COVID-19 vaccines development has been coming thick and fast in the past few days. Today, the Australian government announced a significant breakthrough for the launch of a potential COVID-19 vaccine after AstraZeneca and Oxford University disclosed yesterday that their COVID-19 vaccine candidate proved to be 90% effective.

Besides, two COVID-19 vaccine candidates, by Moderna (NYSE:MRNA) and Pfizer (NYSE:PFE)/BioNTech (NASDAQ:BNTX), recently demonstrated high efficacy against the novel coronavirus.

The Australian government has already secured deals from four frontrunners in the COVID-19 vaccine development. However, the Federal Government said that it would not make the vaccination mandatory.

Besides, the country recorded 0 patients who were in hospitals on ventilator support. This was a significant development, considering the rising number of cases all over the world.

ALSO READ: Qantas (ASX:QAN) to make COVID-19 Vaccine mandatory for travellers

AstraZeneca and Oxford’s COVID-19 Vaccine Buoying Australians Hope

UK-based drugmaker AstraZeneca Plc (LON:AZN) announced that the late-stage clinical trials of its COVID-19 vaccine candidate showed 90% effectiveness against the coronavirus.

Image Source: © Kalkine Group 2020

    Image Source: © Kalkine Group 2020

AstraZeneca and Oxford’s COVID-19 vaccine candidate is likely to be a relatively cheap and easy-to-store product.

The Company disclosed that findings are based on the interim analysis of the clinical trials performed in the UK and Brazil.

It is noteworthy to mention that the vaccine can be stored, transported, and handled at normal refrigerated conditions (2-8°C/ 36-46°F) for minimum six months and administered within the existing healthcare settings.

The Company will now immediately prepare the regulatory submission of the data to worldwide authorities having a framework in place for conditional or early approval.

AZN will seek for an Emergency Use Listing from the WHO for an accelerated pathway to availability of vaccine in low-income nations.

Australians to get COVID-19 Vaccines in March 2021

Health Minister Greg Hunt stated that interim results of AstraZeneca’s vaccine candidate gave Australia a pathway not just to become COVID-safe, but an entirely safe country and a return to normal. Mr Hunt said immunisations for healthcare workers would commence in March 2021 followed by the aged people.

The Health Minister added-

Australia Secured Four COVID-19 vaccine 'deals

Australia has signed supply agreements with four major vaccine developers, and the government has also committed to being a part of the COVAX facility, which is a global agreement for equal distribution of COVID-19 vaccines across the world.

  • Deal with AstraZeneca for the expected manufacture of ~30 million doses of vaccine candidate of the Oxford University AZD1222.
  • A deal for 10 million potential COVID-19 vaccines of Pfizer/BioNTech.
  • Acquired 40 million doses of NVX-CoV2373, COVID-19 vaccine candidate of Novavax.
  • Deal with University of Queensland/CSL’s for the supply of 51 million doses of COVID-19 vaccine.

The Prime Minister said the by securing several COVID-19 vaccines from the frontrunners, and the government is providing Australians with the best shot at early access to a vaccine should the clinical trials prove to be successful.

 

 


Disclaimer
The website https://kalkinemedia.com/au is a service of Kalkine Media Pty. Ltd. (Kalkine Media) A.C.N. 629 651 672. The principal purpose of the content on this website is to provide factual information only and does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) or engage in any investment activity under discussion. We are neither licensed nor qualified to provide investment advice through this platform. In providing you with the content on this website, we have not considered your objectives, financial situation or needs. You should make your own enquiries and obtain your own independent advice prior to making any financial decisions.
Some of the images that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed on this website unless stated otherwise. The images that may be used on this website are taken from various sources on the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image. The information provided on the website is in good faith, however Kalkine Media does not make any representation or warranty regarding the content, accuracy, or use of the content on the website.

 

   
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK